Our team

Karin has over 25 years’ experience with a sustained track record of successful leadership roles within the life sciences, biotech and therapeutic industries at Exelixis, Inc., Millennium Pharmaceuticals, Thermo Fisher Scientific, Horizon Discovery Group plc and PredictImmune Ltd. Karin has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on clinical products and has additional experience in legal, commercial and regulatory pathways. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.

Becoming a Successful Leader in the Life Sciences – Technology Networks featuring Dr. Karin Schmitt 

Joe began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner’s (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in molecular and cellular biology from the University of Bath and an MPhil in business management from the University of Cambridge.

Leading the Movement Towards Direct Cell Conversion – Technology Networks featuring Joe Foster. 

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Pierre-Louis has a background in biochemistry and pharmacology from the University of St Andrews and the University of Oxford. He previously worked in early stage venture development and investment at Oxford Sciences Innovations (OSI) and Deep Science Ventures (DSV) before becoming the first employee at Mogrify.

Cell Therapy – Falling short of its potential? – Drug Discovery World featuring Pierre-Louis Joffrin

Owen is world expert in the application of machine learning and complex systems in cell reprogramming. He was a career development fellow at the Medical Research Council, UK and was the recipient of a Japan Society for Promotion of Science fellowship to work at the RIKEN Omics Science Centre in Yokohama. He is now an Assistant Professor at the Duke-NUS Medical School in Singapore.

Jose has worked at the cutting-edge of cell reprogramming for over a decade. He graduated his PhD at the Albert Einstein College of Medicine in New York before becoming a research fellow at the Harvard Stem Cell Institute. He was awarded a NHMRC career development fellowship, a Charles Viertel Senior Medical Research fellowship as well as an ARC future fellowship and is now a Professor at Monash University.